- Home
- MYGN vs RELY Comparison
MYGN vs RELY Comparison
Compare MYGN & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- RELY
- Stock Information
- Founded
- MYGN 1991
- RELY 2011
- Country
- MYGN United States
- RELY United States
- Employees
- MYGN N/A
- RELY N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RELY Computer Software: Prepackaged Software
- Sector
- MYGN Health Care
- RELY Technology
- Exchange
- MYGN Nasdaq
- RELY Nasdaq
- Market Cap
- MYGN 2.0B
- RELY 3.9B
- IPO Year
- MYGN 1995
- RELY 2021
- Fundamental
- Price
- MYGN $13.36
- RELY $22.61
- Analyst Decision
- MYGN Hold
- RELY Buy
- Analyst Count
- MYGN 12
- RELY 8
- Target Price
- MYGN $23.92
- RELY $22.75
- AVG Volume (30 Days)
- MYGN 1.1M
- RELY 1.6M
- Earning Date
- MYGN 11-07-2024
- RELY 02-19-2025
- Dividend Yield
- MYGN N/A
- RELY N/A
- EPS Growth
- MYGN N/A
- RELY N/A
- EPS
- MYGN N/A
- RELY N/A
- Revenue
- MYGN $823,600,000.00
- RELY $1,176,826,000.00
- Revenue This Year
- MYGN $13.82
- RELY $35.55
- Revenue Next Year
- MYGN $4.59
- RELY $24.22
- P/E Ratio
- MYGN N/A
- RELY N/A
- Revenue Growth
- MYGN 12.15
- RELY 35.18
- 52 Week Low
- MYGN $12.87
- RELY $11.60
- 52 Week High
- MYGN $29.30
- RELY $22.70
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- RELY 70.17
- Support Level
- MYGN $12.87
- RELY $21.17
- Resistance Level
- MYGN $15.44
- RELY $22.67
- Average True Range (ATR)
- MYGN 0.84
- RELY 0.72
- MACD
- MYGN -0.02
- RELY -0.05
- Stochastic Oscillator
- MYGN 12.37
- RELY 96.04
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.